STA Pharmaceutical Co Ltd (WuXi STA) disclosed on Thursday the CMC based development and manufacturing of innovative oncology drugs under a strategic partnership with Antengene Corporation, a biopharmaceutical company focused on the development of new drugs in China and the Asia-Pacific region.
Under the terms of the agreement, Antengene will receive an integrated solution in process R&D and manufacturing using the MAH scheme to accelerate new drug development from WuXi STA.
The collaboration will include both clinical stage and commercial projects, commencing with Phase II/III candidate ATG-008 and then expanding into solid tumor, hematological tumor and viral infection. WuXi STA will provide process R&D and manufacturing from APIs to drug product. Antengene and WuXi STA will explore and expand the collaboration to commercial stage assets as Antengene prepares for the commercialisation of its late-stage pipeline agents.
In addition, ATG-008 is currently in multi-regional clinical trial (MRCT) for the treatment of hepatitis B virus positive (HBV+) advanced hepatocellular carcinoma (HCC) patients (TORCH study). Patient enrollment started in July 2018, stated the partnership.
STA Pharmaceutical Co Ltd (WuXi STA) a pharmaceutical development and manufacturing company and a subsidiary of WuXi AppTec.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval